1. Home
  2. CTXR vs TVRD Comparison

CTXR vs TVRD Comparison

Compare CTXR & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

SELL

Current Price

$0.51

Market Cap

13.4M

Sector

Health Care

ML Signal

SELL

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

SELL

Current Price

$0.99

Market Cap

12.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CTXR
TVRD
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
12.6M
IPO Year
2010
2013

Fundamental Metrics

Financial Performance
Metric
CTXR
TVRD
Price
$0.51
$0.99
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $8.75
AVG Volume (30 Days)
★ 253.3K
184.7K
Earning Date
12-22-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
43.38
★ 79.01
EPS
★ N/A
N/A
Revenue
N/A
★ $911,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$104.18
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 959.30
52 Week Low
$0.37
$0.77
52 Week High
$1.54
$5.69

Technical Indicators

Market Signals
Indicator
CTXR
TVRD
Relative Strength Index (RSI) 48.05 43.90
Support Level $0.47 $0.85
Resistance Level $0.63 $1.09
Average True Range (ATR) 0.06 0.17
MACD -0.00 0.00
Stochastic Oscillator 22.42 20.86

Price Performance

Historical Comparison
CTXR
TVRD

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: